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S U M M A R Y
Objectives: The regulation of the immunopathology of respiratory syncytial virus (RSV) by regulatory T-
cells (CD4+CD25+Foxp3+; Tregs) is not understood.
Methods: To deduce the same, Tregs were depleted in BALB/c mice by injecting anti-CD25 antibody
followed by RSV infection (anti-CD25-RSV mice).
Results: In this model, a decrease in anti-fusion (F) antibody and neutralizing activity, and an increase in
anti-nucleocapsid (N) antibody in serum, were seen. Decreased antibody-dependent cell-mediated
cytotoxicity (ADCC) activity, increased IgG2a, and an inﬂux of activated CD8+ T-cells into the lungs were
also observed. Co-culture of splenic CD45RA+ B-cells from RSV-infected normal mice with CD4+ cells
isolated from anti-CD25-RSV mice (B/CD4) increased anti-F antibody secretion. The inclusion of CD25+
Tregs isolated from isotype Ig-RSV mice into the B/CD4 co-culture substantially enhanced the frequency
of anti-F antibody production. However, the same effect was not seen in the co-culture of CD45RA+ B-
cells with dendritic cells (DCs) (B/DCs) or CD8+ cells (B/CD8) that were obtained from anti-CD25-RSV
mice. The transfer of enriched B-cells from anti-CD25-RSV mice into RSV-infected SCID mice increased
severe lung inﬂammation associated with the increased viral load and eosinophil number.
Conclusions: These results indicate that Tregs modulate B-cell activity, particularly in producing F-
speciﬁc neutralizing antibodies, to regulate RSV-mediated exacerbated diseases.
 2015 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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jou r nal h o mep ag e: w ww .e lsev ier . co m / loc ate / i j id1. Introduction
Respiratory syncytial virus (RSV) induces severe bronchiolitis
and pneumonia in children and older adults worldwide,1–3 and
symptomatic reinfections are frequent in healthy people.4 The
attachment (G) and fusion (F) glycoproteins of RSV project outward
from the viral envelope and mediate viral binding and penetration
into the cell, respectively.5 The antibodies against G and F can
neutralize RSV infection and provide resistance upon passive
transfer. Thus, antiviral therapy against RSV has focused on the F
and G proteins.6* Corresponding author. Tel.: +886 37 246166x37738.
E-mail address: choeyenh@nhri.org.tw (Y.-H. Chow).
http://dx.doi.org/10.1016/j.ijid.2015.10.026
1201-9712/ 2015 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).CD8+ cytotoxic T-lymphocytes (CTLs) confer protection against
RSV infections,7 and also inhibit lung eosinophilia induced by RSV
vaccine.8 The number of CD8+ CTLs and the production of
neutralizing antibody are key factors in the control of RSV-
mediated pathogenesis.9 However, an excess of CD8+ CTLs
contributing to lung pathogenesis has been observed in mice,7,10
and in human adults who have developed symptoms during RSV
infection.11 Regulatory T-cells (Tregs) play a role in limiting the
immunopathology mediated by pathogen-speciﬁc T-cells through
regulation of the release of pro-inﬂammatory cytokines from
immune cells,12,13 and promote pathogen persistence in certain
cases.14 Five to ten percent of mouse CD4+ T-cells that express the
transcription factor Forkhead box 3 (Foxp3) and the alpha chain of
the interleukin (IL)-2 receptor, CD25,15 are identiﬁed as Tregs. The
depletion of Tregs by anti-CD25 antibody has been demonstratedciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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in mice.16–18 Tregs can also suppress antibody production by non-
autoimmune B-cells19,20 and autoantibody responses of B-cells in
humoral autoimmune diseases such as systemic lupus erythema-
tosus.21 However, little is known about the mechanism by which
Tregs regulate the CD8+ T-cells and B-cells in acute RSV infection.
This study demonstrates a fundamental link between Tregs and
the antigen-speciﬁc antibody response in the regulation of the
pathogenesis of RSV infection. CD4+Foxp3+ T-cells were depleted
by anti-CD25 antibody in BALB/c mice followed by RSV infection
(anti-CD25-RSV mice). In this model, a decrease in splenocytic
CD4+Foxp3+ T-cells associated with a decrease in anti-F antibody
titer and an increased inﬂux of pulmonary CD8+ T-cells resulting in
enhanced inﬂammation in the lungs was observed. The modula-
tion of B-cell antigenicity by Tregs in a CD4+ T-cell-dependent
manner that contributed to the control of RSV-induced pathogen-
esis was conﬁrmed.
2. Materials and methods
2.1. Animals, cell lines, and viruses
Six- to eight-week-old BALB/c (H-2Kd) and CB17scid (SCID) mice
were purchased from the National Laboratory Animal Center,
Taiwan. Human larynx carcinoma cells (HEp-2) and BCH4 cells, a
persistently RSV-infected mouse ﬁbroblast cell line, were kindly
donated by Dr Barney S. Graham, National Institute of Allergy and
Infectious Diseases, National Institutes of Health, USA. HEp-2 and
BCH4 were grown and maintained in Dulbecco’s modiﬁed Eagle’s
medium (DMEM; Hyclone) supplemented with 10% fetal bovine
serum (FBS). All the cell lines were cultured in an incubator
maintained at 37 8C and equilibrated with 5% CO2. The propagation
of human RSV-B1 strain VR-1580 (purchased from the American
Type Culture Collection (ATCC)) in HEp-2 cells has been described
previously.22 The titer (plaque-forming units per milliliter, PFU/
ml) of virus was determined by conducting a standard plaque
assay.22
2.2. Depletion of Tregs and RSV challenge of mice (anti-CD25-RSV
mice)
BALB/c mice were injected intraperitoneally twice with 250 mg
of anti-CD25 antibody or isotype-matched immunoglobulin (Ig)
(BD Pharmingen) on day 3 or day 18, and were inoculated
intranasally with 1  104 PFU of RSV on day 0 and 5  106 PFU of
RSV on day 21. The mice were sacriﬁced on day 28. Splenocytes
were isolated and stained with anti-CD4 antibody conjugated with
phycoerythrin (PE)-Cy5 and anti-CD25 antibody conjugated with
ﬂuorescein isothiocyanate (FITC) (eBioscience), followed by
subsequent ﬁxation and permeabilization. These cells were further
stained with PE-conjugated anti-Foxp3 antibody (eBioscience).
After staining and washing, the samples were analyzed by ﬂow
cytometry (BD FACSCalibur).23
2.3. Antibody-dependent cell-mediated cytotoxicity (ADCC) assay
The ADCC assay was conducted using the CytoTox 96 non-
radioactive cytotoxicity assay kit (Promega). Splenocytes from
BALB/c mice were puriﬁed as the effector and BCH4 cells were used
as the target. The assay entailed culturing 2  104 BCH4 cells per
well with diluted serum at 37 8C for 30 min, following by co-
culture with 2  106 splenocytes per well at 37 8C for another 4 h.
After incubation, the culture supernatants were harvested and
mixed with a lactate dehydrogenase (LDH) substrate in a fresh 96-
well ELISA plate for 30 min. For total lysis control, the lysis reagent
was added to the wells prior to the addition of the LDH substrate.The reaction was stopped by adding 2 N H2SO4 and the absorbance
was measured at 490 nm wavelength using a microplate reader
(SpectraMax M2).
2.4. Adoptive transfer of B-cells into SCID mice
Splenocytes were isolated from anti-CD25-RSV or isotype Ig-
RSV mice and negatively selected for untouched B-cells using the
Dynabeads Mouse CD43 kit, following the manufacturer’s instruc-
tions (Invitrogen). The puriﬁed B-cells were stained with anti-
CD45RA antibody conjugated with PE (BD Pharmingen), anti-CD25
antibody conjugated with FITC, and anti-CD27 antibody conjugat-
ed with FITC (eBioscience) for ﬂow cytometry analysis. SCID mice
were injected intravenously with 3  107 puriﬁed CD45RA+ B-cells
(day 0), followed by challenge with 5  106 PFU of RSV (day 3), and
were sacriﬁced on day 8 post challenge and the tissues collected for
further analysis.
2.5. Isolation of dendritic cells
The tibias of anti-CD25-RSV mice were isolated and incubated
with lymphocyte culture medium (LCM; RPMI containing 5% FBS).
The myeloid tissues were removed from the tibia with LCM and
ﬁltered through a 40-mm cell strainer (BD Falcon). The ﬁltrates
were centrifuged and the cell pellet was resuspended in 2 ml RBC
lysis solution (eBioscience) and incubated for 5 min, followed by
the addition of 10 ml of 1 phosphate buffered saline (PBS). The
cells were centrifuged, washed once with 1 PBS, resuspended in
LCM containing 100 U/ml granulocyte-macrophage colony stimu-
lating factor (GM-CSF), and cultured for 7 days. The cells were
pulsed with 1  105 UV-inactivated RSV one day before in vitro co-
culture with isolated B-cells.
2.6. Co-culture of RSV-primed B-cells and ELISPOT assay for anti-F
antibody and cytokines
Untouched B-cells were negatively isolated from anti-CD25-
RSV mice using the Dynabeads Mouse CD43 kit. Splenocytic CD4+
(Treg-depleted) T-cells and CD8+ T-cells were isolated from anti-
CD25-RSV mice using the Dynabeads Flow Comp Mouse CD4 kit
and Dynabeads Untouched Mouse CD8 kit (Invitrogen), respec-
tively. CD25+ (Treg) cells were isolated from the spleens of isotype
Ig-RSV mice using the Dynabeads Flow Comp Mouse CD25 kit.
RSV-primed B-cells (5  105) were cultured alone or were co-
cultured with 103 Tregs from isotype Ig-RSV mice, or 5  104 CD4+
(Treg-depleted) T-cells, or 5  104 CD8+ T-cells, or 1  105 dendritic
cells (DCs) (B, B/Treg, B/CD4, B/CD8, or B/DCs, respectively) from
anti-CD25-RSV mice in individual wells of 96-well ﬁltration plates
(Millipore) pre-coated with recombinant RSV F protein (0.2 mg/well)
(Sino Biological Inc.) and blocked with conditioned medium (CM) for
1 h. In another set of co-cultures (B/CD4, B/CD8, and B/DCs), Tregs
puriﬁed from isotype Ig-RSV mice were also included. After 16–18 h
of incubation, the plates were washed three times with washing
buffer (PBST, 0.05% Tween20 in PBS). Biotinylated anti-mouse IgG
(Vector Laboratories) was subsequently added and the plates
incubated for 2 h. After washing, avidin–horseradish peroxidase
(HRP; eBioscience) was added and incubated for 45 min. Finally, AEC
substrate (3-amine-9-ethylcarbazole; Sigma-Aldrich) was added
and allowed to react for 30 min in the dark. The number of spots per
well was scored using the ImmunoSpot reader (CTL ImmunoSpot,
Cellular Technology Ltd).
2.7. ELISA
Ninety-six-well plates were coated with 50 ng per well of
recombinant F protein (Sino Biological Inc.) to capture anti-F
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capture total mouse IgG, or with 5  104 PFU per well of heat-
inactivated RSV (HI-RSV) to capture RSV-speciﬁc IgG in serum.
Serially diluted serum were added to the wells and incubated for
2 h. After washing with PBST, HRP-conjugated donkey anti-
mouse IgG antibody (Jackson ImmunoResearch) was added to
the wells for 45 min. For detecting anti-RSV IgG, IgG1, and
IgG2a, serially diluted samples were added to the plates coated
with HI-RSV and then detected by the addition of HRP-
conjugated goat anti-mouse IgG, anti-mouse IgG1 (Zymed),
and anti-mouse IgG2a (Zymed), respectively. The reaction was
developed by incubation with 3,30,5,50-tetramethylbenzidine
(TMB) substrate for 20 min in the dark and terminated by adding
2 N H2SO4. The optical density at 450 nm was determined using
a microplate reader.
2.8. Western blot
HI-RSV particles at 2  105 PFU were loaded per well of
sodium dodecyl sulfate (SDS)–polyacrylamide gel, electrophor-
esed, and then transferred onto a nitrocellulose membrane
(Amersham). The membrane was incubated with 5% skimmed
milk at 4 8C for overnight with diluted polyclonal sera from anti-
CD25-RSV or isotype Ig-RSV mice as the primary antibody. The
membrane was washed three times with PBST, and an HRP-
conjugated donkey anti-mouse polyclonal serum (Jackson
ImmunoResearch) was subsequently added to the membrane.
After 1 h of incubation, the membrane was washed twice with
PBST and then treated with ECL chemiluminescent substrate
(Millipore) and developed by autoradiography. The bands were
analyzed using ImageJ software and the results of the analysis
were presented as a graph.
2.9. Preparation of lung homogenate
The isolated lung tissues were incubated with 300 U/ml
collagenase type 2 (Worthington) and 15 mg/ml DNase I (Roche) at
37 8C for 1 h before homogenizing with a mesh. The homogenate
was centrifuged at 1000 rpm for 5 min at 4 8C to sediment the
pulmonary cells. The cells were washed and resuspended in PBS.
For inﬁltrated CD8+ T-cell staining, pulmonary cells were
stained with the FITC-conjugated anti-CD8 antibody (eBioscience)
and PE-conjugated anti-CD69 antibody (BD Pharmingen), followed
by ﬁxation. After washing, the samples were analyzed by ﬂow
cytometry. For B-cell or macrophage staining, the pulmonary cells
were stained with rat anti-mouse CD45RA antibody or anti-mouse
F4/80 antibody (AbD), respectively, followed by staining with anti-
rat IgG antibody conjugated with PE-Cy7 for 30 min. After washing,
the samples were analyzed by ﬂow cytometry.
2.10. Real-time PCR
Lung RNA was extracted using RNAzol (Molecular Research
Center, Inc.) and then mixed with random primers and SuperScript
III reverse transcriptase (Invitrogen) and incubated at 25 8C for
5 min, 50 8C for 50 min, and 70 8C for 15 min. The resulting cDNA
was subjected to quantitative PCR analysis (LightCycler 480 Real-
Time PCR system) with RSV N speciﬁc primer pairs forward 50-
aagatgcaaatcataaattcacagga-30 and reverse 50-tgatatccagcatctt-
taagtatctttatagtg-30, normalized to the mouse actin gene as
internal control using the primer pairs forward 50-accaactgggac-
gacatggagaa-30 and reverse 50-tagcacagcctggatagcaacgta -30. The
numbers of cycles (Ct) required for ampliﬁcation of the N gene and
actin were calculated. The relative expression of the N gene was
calculated as follows: the individual Ct for the RSV N gene obtained
from anti-CD25- or isotype Ig-treated mouse lungs was normalizedto the respective Ct for the control gene (actin). To detect IL-13 in
the lungs, primer pairs speciﬁc to IL-13, forward 50-aggagcttatt-
gaggagctgagca-30 and reverse 50-tggagatgttggtcagggaatcca-30, and
probes 50-FAM-tgcaacggcagcatggtatggagtgt-30TAMRA, were used.
All the primer sets were synthesized commercially by Genomics
BioSci & Tech Ltd, Taiwan.
2.11. Immunohistochemistry
Whole lungs were excised from the mice, ﬁxed in 10%
formalin solution (Sigma-Aldrich) overnight, and embedded in
parafﬁn for sectioning. The sections were stained with hematox-
ylin and eosin (HE) or with rat monoclonal anti-major basic
protein (MBP) antibody (provided by Dr James J. Lee, Mayo Clinic,
Scottsdale, AZ, USA), followed by the appropriate secondary
antibodies. Twenty bright-ﬁeld pictures of each section were
taken at 200 magniﬁcation (Nikon DXM1200 CCD digital
camera) and the number of eosinophils was counted. The mean
eosinophil count for each section was calculated. The severity of
inﬂammation in tissue sections was scored using criteria
reported previously.24
2.12. Statistical analysis
The unpaired two-tailed t-test and paired Student’s t-test were
used to compare the results obtained from the various experimen-
tal groups. The results were considered statistically signiﬁcant
when p < 0.05. The symbols *, **, and *** are used to indicate
p < 0.05, p < 0.01, and p < 0.001, respectively.
3. Results
3.1. Anti-CD25 treatment decreases the anti-F but not the anti-N
antibody titer in mice challenged with RSV
The treatment of mice with anti-CD25 antibody to deplete Tregs
followed by RSV infection (anti-CD25-RSV) in order to study the
role of Tregs in RSV-induced pathogenesis was established. The
depletion of CD25+ T-cells in anti-CD25-RSV mice compared to
isotype Ig-RSV mice was conﬁrmed. Anti-CD25-RSV mice had a
reduced number of splenocytic CD4+CD25+ T-cells (Figure 1A; 0.5%
vs. 4.1% in the control) and CD4+CD25+Foxp3+ Tregs (Figure 1B;
0.8% vs. 2.1% in the control).
The collected sera were analyzed for their ability to bind to RSV
antigens by Western blot. The sera from isotype Ig-RSV mice were
able to bind to many RSV proteins including the G (89 kDa), F (54–
63 kDa), and N (35 kDa) proteins. It was observed that the titer of
anti-F antibodies decreased in anti-CD25 infected mice, compared
to isotype Ig-RSV mice. In the isotype Ig-RSV mice, the signal for F
protein was strong in four out of ﬁve mice, whereas one mouse
showed a weaker signal. In anti-CD25-RSV mice, two out of ﬁve
mice showed a strong signal, two out of ﬁve mice showed a weak
signal, and one mouse showed no reactivity at all to RSV F protein
(Figure 1C). ImageJ analysis of the bands showed that the antibody
response to RSV F antigen was reduced by half in anti-CD25-RSV
mice, whereas the anti-N antibody response was increased about
5-fold in anti-CD25-RSV mice compared to isotype Ig-RSV mice.
There was no change in binding to RSV G protein between anti-
CD25-RSV mice and isotype Ig-RSV mice (Figure 1C). The F and N
antigens were identiﬁed by mass spectrophotometry analysis
(Supplementary Material, Figure S1).
In line with this observation, the ELISA results also conﬁrmed
that the anti-F antibody titer was decreased in anti-CD25-RSV mice
compared to isotype Ig-RSV mice (Figure 1D). The anti-G antibody
titer was not altered (data not shown). These results imply that the
production of anti-F antibodies is impaired in Treg-depleted mice.
Figure 1. Decreased anti-F and increased anti-N antibody response in anti-CD25-RSV mice. Flow cytometry analysis of splenocytes from individual anti-CD25-RSV mice and
isotype Ig-RSV mice depicting the percentage of (A) CD4+CD25+ T-cells and (B) CD4+CD25+Foxp3+ Tregs in the splenocytes. (C) Western blot analysis of HI-RSV with the sera
collected from anti-CD25-RSV mice or isotype Ig-RSV mice to react towards F, N, and G antigens of RSV. Commercial antibodies against F and G were included as reference. The
relative intensities of signal from individual serum-blotted G, F, and N proteins were analyzed using ImageJ software and presented as graphs. (D) Sera collected from anti-
CD25-RSV mice (&) and isotype Ig-RSV mice (*) were assayed for binding to recombinant RSV F protein by ELISA. Data are representative of the results derived from two
independent experiments.
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measured in the sera (Fig. 2). The amount of total IgG (Figure 2A)
was comparable in both the groups. RSV-speciﬁc IgG (Figure 2B)
and IgG2a (Figure 2D) were enhanced in anti-CD25-RSV mice sera,Figure 2. Depletion of CD25+ T-cells enhances RSV-speciﬁc IgG2a, but not RSV-speciﬁc IgG
(*) on day 28 were serially diluted and assayed for binding to total mouse IgG (A), RSV-sp
representative of the results derived from three independent experiments.but not RSV-speciﬁc IgG1 (Figure 2C), leading to an increased
IgG2a/IgG1 ratio, which is known to promote the Th1 response.
The depletion of Tregs has been known to promote the Th1
immune response,25 as observed in the present mouse model.1 or total IgG. Sera collected from anti-CD25-RSV mice (&) and isotype Ig-RSV mice
eciﬁc IgG (B), RSV-speciﬁc IgG1 (C), and RSV-speciﬁc IgG2a (D) by ELISA. The data are
Figure 3. Reduced neutralizing activity and ADCC activity in anti-CD25-RSV mice sera. (A) RSV pre-mixed with individual mouse sera collected from anti-CD25-RSV mice or
isotype Ig-RSV mice on day 28 was allowed to infect cells and form plaques in a plaque-forming assay. The difference in the number of PFUs reﬂects the RSV neutralizing
ability of the respective sera. (B) ADCC activity in the sera was assayed. In brief, the target cells were cultured in the presence of mice sera and then co-cultured with the
effector cells. The amount of LDH released in the culture supernatant represented the ADCC activity. (C) ADCC activity in the sera serially diluted from 1:20 to 1:500.
Figure 4. The effect of T-cells from anti-CD25-RSV mice on the antigenicity of B-
cells from RSV-immunized normal mice in a co-culture. Splenocytic B-cells were
puriﬁed from RSV-infected normal BALB/c mice. The puriﬁed CD45RA+ B-cells were
co-cultured with CD4+ or CD8+ T-cells (Treg-depleted), or DCs from anti-CD25-RSV
mice either alone or in combination with CD25+ T-cells (Treg) from isotype Ig-RSV
mice. After 5 days, the frequency of B-cells secreting anti-F antibody was estimated
by ELISPOT assay.
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mice
RSV pre-incubated with sera from anti-CD25-RSV mice formed
a greater number of plaques than RSV pre-incubated with isotype
Ig-RSV mice sera (Figure 3A). This indicates that the neutralizing
activity against RSV is reduced and is correlated to the reduction in
anti-F antibody in the sera from anti-CD25 RSV mice (Figure 1C, D).
ADCC involves predominantly natural killer (NK) cells and also
neutrophils and monocytes or macrophages to limit and control
infection.26 RSV antibodies induced in the body are known to have
potent ADCC activity.27 It was found that the ADCC activity in the
sera from anti-CD25-RSV mice was reduced, compared to the sera
from isotype Ig-RSV mice (Figure 3B). ADCC activity in anti-CD25-
RSV mice sera decreased in a dose-dependent manner; the
maximum difference between the two groups of mice was seen
at 1:20 dilution (Figure 3C). These results indicate that anti-CD25
treatment inﬂuences the titer as well as the functional potency of
the antibodies.
3.3. Tregs play a crucial regulatory role in determining the B-cell
response to RSV
Splenocytic B-cells were puriﬁed from RSV-infected normal
BALB/c mice. Post-enriched B-cells were stained for CD45RA
expression and showed 98.4% purity (data not shown). CD45RA+
B-cells were co-cultured with CD4+ or CD8+ (Treg-depleted) T-cells
from the spleen, or DCs from the tibia of anti-CD25-RSV mice. After
5 days of co-culture, the frequency of B-cells secreting anti-F
antibody was assayed by ELISPOT capture of recombinant F
protein. Groups of B, B/CD4, B/CD8, and B/DC cultures were set up,
or alternatively substituted with CD25+ T-cells (Tregs) from
isotype Ig-RSV mice. In B-cell culture alone, 50–60 spots wereobserved, whereas 125–150 spots were seen in B/CD4 (Treg-
depleted) culture and 150–175 spots in B/CD4 with Tregs (from
isotype Ig mice) culture; however very low numbers of spots (50 or
less) were observed in B/CD8 and B/DC cultures (Figure 4). This
indicates an increase in the number of B-cells secreting anti-F
antibody in B-cells cultured with Tregs. These results suggest that
Treg modulation of anti-F antibody production by B-cells is CD4+
T-cell-dependent, but CD8+ T-cell- and DC-independent.
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inﬂux of CD8+ T-cells
Tregs limit RSV-induced pulmonary immunopathology by
suppressing CD8+ T-cell function.28,29 To conﬁrm this, the tissue
pathology and CD8+ T-cell inﬂux into the lungs of anti-CD25-RSV
mice were monitored. Four days after RSV infection, an increased
percentage of total CD8+ T-cells (Figure 5A) and activated CD8+
T-cells (CD8+CD69+ T-cells; Figure 5B) were found to have
inﬁltrated into the lungs of anti-CD25-RSV mice, compared to
isotype Ig-RSV mice. The lung sections obtained from anti-CD25-
RSV mice on day 28 showed more inﬂammation compared to those
from isotype Ig-RSV mice (Figure 5C). The severity of lung
inﬂammation was quantiﬁed and found to be enhanced in anti-
CD25-RSV mice (Figure 5D).
3.5. Enhanced lung pathology in SCID mice receiving B-cells from anti-
CD25-RSV mice
To investigate whether the B-cells impaired in F-speciﬁc
antibody production participate in RSV-induced lung pathology,
splenic CD45RA+ B-cells isolated from anti-CD25-RSV mice on day
28 were injected intravenously into immunocompromised
CB17scid mice, which are deﬁcient in both T and B lymphocytes
but have normal NK cells, macrophages, and granulocytes.30 SCID
mice were infected with RSV 2 days after receiving CD45RA+
B-cells, and the course of infection was monitored. B-cells obtained
from both isotype Ig-RSV and anti-CD25-RSV mice had approxi-
mately 3% memory B-cells (CD27+CD45RA+) (Supplementary
Material, Figure S2B).
Increased eosinophil counts were observed in the lungs of SCID
mice that received B-cells from anti-CD25-RSV mice, compared to
the recipients of isotype Ig-RSV mice B-cells (Figure 6A). This wasFigure 5. Depletion of CD25+ cells enhances lung pathology and CD8+ T-cell inﬂux. Pulmo
anti-CD8 antibody or (B) anti-CD8 and anti-CD69 antibodies, and analyzed by ﬂow cyto
representative of the results derived from three independent experiments. (C) The lun
individual sections were analyzed under 200 magniﬁcation. The severity of the lung pat
for individual mice in each group. Similar results from two independent experiments wconsistent with increased IL-13 expression in the former
(Figure 6B). RSV infection associated with pulmonary eosinophilia
is known to cause bronchiolitis in children,31 and IL-13 is required
for eosinophil entry into the lungs.32 Severe bronchiolitis
associated with lymphocyte inﬁltration was observed in lung
tissue sections of RSV-infected SCID mice that received B-cells
from anti-CD25-RSV mice, whereas reduced inﬂammation was
observed in SCID mice that received B-cells from isotype Ig-RSV
mice (Figure 6C). The severity of lung inﬂammation was scored for
both groups (Figure 6D).
Lung viral loads detected by real-time reverse transcriptase PCR
on day 3 post challenge showed an increase in SCID mice that had
received anti-CD25-RSV mice B-cells, compared to SCID mice that
had received isotype Ig-RSV mice B-cells (Figure 6E). These results
conﬁrm that the depletion of Tregs impaired B-cell activity in the
production of anti-F antibodies to clear the lung viral load, which
induced lung inﬂammation. Tregs modulate B-cell activity by
attenuating antibody production, the effect of which culminates in
the modiﬁcation of RSV load in the infected animals.
4. Discussion
The vaccination of infants and children with formalin-inactivated
RSV vaccine (FI-RSV) resulted in intense inﬂammatory inﬁltrates
including eosinophilia in the lungs of the vaccine recipients,
indicating that the anti-RSV antibodies generated had poor
neutralizing activity.33,34 Reinfection with RSV leads to exacerbated
disease, similar to the pathogenesis of dengue hemorrhagic fever,
and antibody-dependent enhancement of non-neutralizing anti-
bodies supposedly helps to increase the viral load as well as the
immunopathology.35 In the present study, upon depletion of Tregs, a
decrease in neutralizing antibodies accompanied by an increase innary cells isolated from anti-CD25-RSV or isotype Ig-RSV mice were stained with (A)
metry. The percentage of CD8+ or CD8+CD69+ T-cells was calculated. The data are
g sections were prepared and stained with hematoxylin and eosin. Pictures from
hology in each section was graded and given a score. (D) Representation of the score
ere obtained, and one of the results is shown.
Figure 6. Enhanced lung pathology in SCID mice receiving B-cells from anti-CD25-RSV mice. (A) Representation of the number of eosinophils in the lung sections of the SCID
mice stained with anti-MBP antibody. (B) The relative expression of IL-13 in the lungs of the SCID mice on day 3 post challenge was quantiﬁed by real-time reverse
transcriptase PCR and normalized to actin gene expression. Similar results were obtained from two independent experiments. (C) Representation of the hematoxylin and
eosin-stained lung sections; pictures were taken at 200 magniﬁcation. (D) Representation of the severity of the pathology in each section graded based on the score. Similar
results from two independent experiments were obtained, and one of them is shown. (E) Representation of the lung viral load quantiﬁed by real-time reverse transcriptase
PCR using primers speciﬁc to the RSV N gene and normalized to actin gene expression.
H.-Y. Shao et al. / International Journal of Infectious Diseases 41 (2015) 56–6462non-neutralizing antibodies resulting in enhanced pathogenesis of
RSV infection was observed.
Tregs have been proven to play a crucial role in modulating the
pathogenesis of RSV infection.28 They modulate B-cell antibody
responses,36 suppress antibody production,37 and induce B-cell
death.19,38 In this study it was demonstrated that the depletion of
CD4+CD25+Foxp3+ Tregs in mice using anti-CD25 antibody prior to
RSV infection resulted in decreased generation of anti-F antibody
(Figure 1), which is critical in providing the protection against RSV
infection,39 and also in decreased neutralizing antibodies and
ADCC activity (Figure 3), but an increase in non-neutralizing
antibodies such as anti-N (Figure 1). Non-neutralizing antibodies
induced by RSV or its vaccine enhance infection and cause immune
complex deposition, leading to exacerbated respiratory disease.40
A higher ratio of neutralizing to non-neutralizing antibodies
improves the balance of the responding virus-speciﬁc responses
during RSV infection.41 In the present study, Tregs depletion was
found to interfere with the balance of the antibody response (anti-
F/anti-N), thereby impairing clearance of RSV, leading to enhanced
immunopathogenesis (Figure 5). A direct impact of B-cells on Tregs
has also been reported; the suppression of autoimmune disease in
the B-cell-depleted (treatment with CD20-speciﬁc antibody) NOD
(non-obese diabetes) mouse model is accompanied by an increase
in CD25+Foxp3+ Tregs.42–44 Besides CD25 expressed in CD4+
T-cells, the B-cell subset expressing CD25 has a unique phenotype
in mice45 and in humans.46 CD25+ B-cells have been indicated to
behave like memory B-cell populations in humans47 and in mice.48
B-cells in anti-CD25-RSV mice vs. isotype Ig-RSV mice were
examined and it was found that there was no difference in thenumber of CD45RA+ (total B) and CD27+CD45RA+ (memory) B-cells
in the two groups (Supplementary Material, Figure S2A and S2B)
. Therefore, it was proven that epitope-speciﬁc B-cell activity is
modulated by Tregs but not by memory B-cells.
Tregs might suppress speciﬁc T-cell responses by inhibiting
their proliferation49 and by acting directly at the site of T-cell
activation.50 The depletion of Tregs in mice by anti-CD25 antibody
treatment followed by vaccinia virus (VV) infection resulted in an
increase in the immunodominant B8R (a protein encoded by the
B8R open reading frame of VV, epitope20–27)-speciﬁc cells and
skewed the immune response towards short-lived effector CD8+
T-cells.51 This observation supports the present results showing an
increase in proliferation and activation of CD8+ T-cells and their
acute inﬁltration into the lungs of anti-CD25-RSV mice (Figure 5).
However, the adoptive transfer of B-cells from anti-CD25-RSV mice
into SCID mice followed by RSV infection resulted in increased lung
inﬂammation (Figure 6), indicating that Tregs are involved in the
regulation of B-cell antigen-speciﬁc antibody production, thereby
affecting RSV-induced pathogenesis. CD8+ T-cells are not involved
in this event.
Tregs are known to inhibit the blast activity and proliferation of
B-cells in vitro.52 The direct suppression of the T-cell-dependent B-
cell Ig response by CD4+CD25+ T-cells has also been reported.20
However, in vitro co-culture of RSV-primed B-cells with Treg-
depleted CD4+ T-cells in the presence of Tregs (Figure 4)
synergistically increased the frequency of anti-F secretion,
suggesting that Tregs might play a role in the CD4+ T-cell-
dependent modulation of B-cell antigenicity rather than the
inhibition of antibody production during RSV infection. Another
H.-Y. Shao et al. / International Journal of Infectious Diseases 41 (2015) 56–64 63study has also shown that Treg depletion severely reduces the
follicular T helper (Th) cell response to inﬂuenza virus and
decreases the frequency and number of nuclear protein-speciﬁc
germinal center B-cells.53 Tregs can directly interact with B-cells
and suppress B-cell Ig production and Ig class switch recombina-
tion. They can also suppress Th cells thereby indirectly affecting
the B-cell response.20 In the present study, Tregs appeared to
differentially modulate the B-cell response against different RSV
antigens or alter the ratio of different IgG isotypes in the course of
infection.
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